New revenue, earnings sources need to emerge from pharma R&D … - Forbes
New revenue, earnings sources need to emerge from pharma R&D …Forbes, NY - 10 hours ago… patent expiry and further generic competition may occur in the second half for blockbuster drugs, Pfizer's Zyrtec and GlaxoSmithKline's Coreg, Fitch said.Fitch Pharma R&D Quarterly: Laying the Pipeline for the Future PharmaLive.com (press release)all 9 news articles
Read full story